Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T20:32:33.859Z.
Calculation as of: 2026-10-06T20:32:33.859Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2e4cd533ac20a6f80cd606aebe48acc9b54aed9ffabeca25d6b8b689be79c8f7
PEG RATIO
N/A
OptimizeRx Corp.
Market Cap
$165.32M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| OptimizeRx Corp. (OPRX) | $165.32M | N/A |
| Nkarta, Inc. (NKTX)vs › | $165.27M | N/A |
| Cue Biopharma, Inc. (CUE)vs › | $168.10M | N/A |
| Quanterix Corporation (QTRX)vs › | $162.04M | N/A |
| MediWound Ltd. (MDWD)vs › | $168.92M | N/A |
| Journey Medical Corporation (DERM)vs › | $169.53M | N/A |
| Minerva Neurosciences, Inc. (NERV)vs › | $159.80M | N/A |
| PepGen Inc. (PEPG)vs › | $159.78M | N/A |
| Precision BioSciences, Inc. (DTIL)vs › | $171.13M | N/A |
| LifeMD, Inc. (LFMDP)vs › | $159.22M | N/A |
PEG Ratio
N/A
P/E Ratio
37.7
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
